预防和治疗胺使用障碍的NMDA受体甘氨酸结合部位调节器
Yu-Chin Hsiao1, Mei-Yi Lee1, Ming-Huan Chan2,3
1Center for Neuropsychiatric Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan.
在大鼠中,N-甲基-D-酸盐受体 (NMDAR) 调节剂D-和萨尔科辛降低了寻找胺的行为. 准NMDAR甘氨酸部位可能治疗胺使用障碍并减少滥用潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 成研究 研究成研究
背景情况:
- 胺是一种快速起作用的抗抑郁药,但具有滥用潜力.
- 胺作为一种非竞争性的N-甲基-D-酸盐受体 (NMDAR) 抗剂.
- NMDAR调制提供了一个潜在的策略,以减轻胺的滥用责任,并治疗胺使用障碍.
研究的目的:
- 调查NMDAR调节剂是否作用于甘氨酸结合部位可以降低对氨酸的动机.
- 评估这些调节剂在减少胺寻求行为和复发方面的有效性.
- 通过将它们与寻求糖糖的行为进行比较来确定这些效应的特异性.
主要方法:
- 训练老鼠自行服用胺.
- 动机被评估使用一个渐进式比率表的胺和糖颗粒.
- 在灭绝后,寻找行为和运动运动活动的恢复被测量.
主要成果:
- D-氨酸和萨科辛显著降低了自给自取氨酸的动机.
- 这些NMDAR调节器阻止了胺寻求行为的恢复.
- 没有观察到对糖颗粒动机,恢复或运动活动的显著影响,这表明特异性.
结论:
- 用D-氨酸和氨酸针对NMDARs的甘氨酸结合部位,特别减少了胺激素的动机和复发.
- 这些发现支持NMDAR甘氨酸位部调节作为对胺使用障碍的有前途的治疗策略.
- 这种方法可能有助于预防胺滥用,并有效治疗成.
更多相关视频
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
